drugset / Trial / NCT00313950

Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine

NCT00313950

Phase 4 Completed 470 enrolled Sanofi Pasteur, a Sanofi Company
RandomizedParallel-groupSingle-blindPrevention

Summary

The present study will explore the immunogenicity of AVAXIM™ 80U-Pediatric in 12-13 months Turkish children and check if the administration of the MMR trivalent vaccine on the same day but at different site will interfere on immunogenicity for the four valences Hepatitis A, Measles, Mumps, and Rubella.

Timeline

Start
2006-09
Primary completion
2009-12
Completion
2010-04

Drugs

EvaluationDrugModalityDoseRoute
Subject AVAXIM Vaccine 0.5 ml Intramuscular